312
Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.
 patients undergoing total hip and total knee arthroplasty: Subject; no increased risk of bleeding: Effect; Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid: Treatment; Dabigatran etexilate: Treatment.Drug; non-steroidal anti-inflammatory drugs: Treatment.Drug; acetylsalicylic acid: Treatment.Drug; total hip and total knee arthroplasty: Treatment.Disorder; non-steroidal anti-inflammatory drugs: Combination.Drug; acetylsalicylic acid: Combination.Drug; Dabigatran etexilate: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients undergoing total hip and total knee arthroplasty: Subject; no increased risk of bleeding: Effect; Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid: Treatment; Dabigatran etexilate: Treatment.Drug; non-steroidal anti-inflammatory drugs: Treatment.Drug; acetylsalicylic acid: Treatment.Drug; total hip and total knee arthroplasty: Treatment.Disorder; non-steroidal anti-inflammatory drugs: Combination.Drug; acetylsalicylic acid: Combination.Drug; Dabigatran etexilate: Combination.Drug